Drugs / Fluviral
Fluviral
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01180621 | Sep → Oct 2010 | influenza | Dalhousie University | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT01878825 | Jul → Aug 2013 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01626820 | Jul → Aug 2012 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01153685 | Jul 2010 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01001325 | Oct 2009 → Mar 2010 | influenza | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT00929331 | Jul → Aug 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00784784 | Nov 2008 → May 2009 | influenza | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT00718120 | Jul → Aug 2008 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00505453 | Jul → Aug 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00232947 | Oct 2005 → Feb 2006 | influenza | ID Biomedical Corporation, Quebec | Completed | No outcome recorded |
| Phase 3 | NCT00216242 | Sep 2005 → May 2007 | influenza | ID Biomedical Corporation, Quebec | Unknown | No outcome recorded |
| Phase 3 | NCT01389479 | Jan → May 2005 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00586469 | Dec 2007 → Jan 2008 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01180699 | Oct 2010 → Aug 2012 | — | University of Alberta | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01140009 Comparator | Aug → Sep 2010 | influenza | University of British Columbia | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00764998 Comparator | Oct 2008 → Apr 2009 | HIV infectious disease, influenza | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03150537 Comparator | May → Jun 2017 | — | brian.ward | Completed | No outcome recorded |
| Phase 4 | NCT02560909 Comparator | Oct 2015 → Feb 2016 | disease related to transplantation | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluviral | “A Non-Inferiority Comparison of Fluviral™ Influenza Vaccine to a U.S. Licensed Inactivated Split-Virion Vaccine (Fluzone®) in Adults ≥ 50 Years Old Living in the Community” NCT00232947 ↗19“A trivalent killed split non-adjuvanted influenza vaccine (Fluviral™) was used.” PMID 21512577 ↗ Mar 2011 |
| Known as | Fluviral influenza vaccine, 2009-2010 | “Fluviral influenza vaccine, 2009-2010” NCT01001325 ↗ |
| Known as | GSK1536489A | “Immunogenicity and Safety Study of GSK Biologicals' (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over...” NCT01153685 ↗2“Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older” NCT01878825 ↗ “Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in Adults Aged 18 Years and Older” NCT01626820 ↗ |
| Modality | Vaccine | “Fluviral, the investigational vaccine” NCT00232947 ↗ |
| Route | Intramuscular | “One dose, Intramuscular injection” NCT00586469 ↗ |